Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310750 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
A Phase 1 study of Plaque Psoriasis, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT02310750 is a Phase 1 study of Plaque Psoriasis that has completed, run by Pfizer. The registered enrollment target is 96 participants, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02310750, a Phase 1 study of Plaque Psoriasis, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic properties of different forms of PF-06700841 may be studied (tablet and solution/suspension forms).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PF-06700841 oral solution/suspension
- DRUG PF-06700841 tablet
Study Locations (1)
California
- Anaheim Clinical Trials, LLC - Anaheim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02310750
The ClinicalTrials.gov registry entry for NCT02310750 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (77% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02310750 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02310750 about?
NCT02310750 is a clinical study titled "A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation". The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the body when given as single and multiple doses. The pharmacokinetic propert...
What is the current status of trial NCT02310750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2014-11. Estimated completion is 2016-02.
What conditions does trial NCT02310750 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT02310750?
The interventions under investigation include: Placebo (OTHER), PF-06700841 oral solution/suspension (DRUG), PF-06700841 tablet (DRUG).
Who is sponsoring clinical trial NCT02310750?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02310750 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
RECRUITING · Phase 1
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
Guselkumab Immunogenetics
RECRUITING · Phase 4
-
Bimekizumab in Plaque Psoriasis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.